Center for Gastric Cancer, National Cancer Center, Goyang, 410-769, Republic of Korea.
Pharmacogenomics. 2014 Feb;15(3):375-84. doi: 10.2217/pgs.13.250.
Gastric cancer is the second most common cause of cancer death worldwide. Recent development of targeted agents provides clinicians with additional systemic treatment options to conventional cytotoxic agents. Predictive markers are undoubtedly important for guiding the appropriate use of targeted and cytotoxic agents. Currently, however, HER2 is the only predictive biomarker validated for gastric cancer. In this review, candidate predictive markers for response to other targeted agents and cytotoxic chemotherapeutic agents are discussed.
胃癌是全球第二大常见癌症死因。靶向药物的最新发展为临床医生提供了除传统细胞毒药物以外的额外系统治疗选择。预测标志物对于指导靶向药物和细胞毒药物的合理应用无疑是非常重要的。然而，目前，HER2 是唯一经过验证可用于预测胃癌的生物标志物。本文就其他靶向药物和细胞毒化疗药物的疗效预测标志物进行综述。
